MagForce AG
frankfurt : MF6

November 22, 2011 11:14 ET

MagForce AG Announces Initiation of Research Coverage by Merchant Securities Limited

BERLIN, GERMANY--(Marketwire - Nov 22, 2011) -

MagForce AG / MagForce AG Announces Initiation of Research Coverage by Merchant Securities Limited . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.

Berlin, November 22, 2011 - MagForce AG (FSE: MF6), a leading medical technology company focusing on nanomedicine in oncology, announced today that Merchant Securities Limited has initiated research coverage on the company and published its first report today. The report is available upon request from MagForce AG and Merchant Securities Limited or at

"We are very pleased that Merchant Securities has taken up coverage of MagForce. The comprehensive report gives investors an independent view of the company, our novel technology for the treatment of brain tumors, and perspectives on our future growth and development" said Dr. Andreas Jordan, Founder and CSO at MagForce. "Merchant's head life science analyst, Dr. Navid Malik, has been following MagForce for some time and is a highly regarded equity research analyst with over fifteen years' experience in the pharmaceutical field, specifically in the area of oncology."


MagForce AG is a leading medical technology company focusing on nanomedicine in oncology. The company's proprietary procedure, NanoTherm® therapy, enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of magnetic nanoparticles. NanoTherm®, NanoPlan®, and NanoActivator™ are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan and NanoActivator are trademarks of MagForce AG in selected countries.


Merchant Securities Group plc offers a broad range of financial services through its Private Client Wealth Management and Investment Banking divisions. The Investment Banking division provides services to UK small and mid-cap companies and institutional investors, with the equity research team currently covering five targeted sectors including Life Sciences. The Life Sciences team is headed by Navid Malik who has over fifteen years' experience within the Pharmaceutical arena. He was awarded two StarMine Analyst Awards in 2011, having been ranked as the number one stock picker in the European Pharmaceuticals sector and number two stock picker in the UK and Ireland Healthcare sector.


This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward- looking statements are based on our current expectations and certain assumptions which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward- looking statements. MagForce AG assumes no obligation to update these forward- looking statements or to correct them in case of developments, which differ from those, anticipated.

--- End of Message ---

MagForce AG Max-Dohrn-Str. 8 Berlin Germany

Listed: Open Market (Freiverkehr) in Frankfurter Wertpapierbörse;

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: MagForce AG via Thomson Reuters ONE


Contact Information

  • Contact:
    Stacy Wiedenmann
    Director Investor Relations & Corporate Communications
    Magforce AG
    Max-Dohrn-Str. 8
    10589 Berlin
    T +49 30 308 380 31
    F +49 30 308 380 99
    M +49 151 12000 722